| Drug General Information |
| Drug ID |
D0H9MA
|
| Former ID |
DIB001337
|
| Drug Name |
COR-1
|
| Indication |
Heart failure [ICD9: 428; ICD10:I50]
|
Phase 2 |
[1]
|
|---|
| Company |
Corimmun GmbH
|
| Target and Pathway |
| Target(s) |
Beta-1 adrenergic receptor |
Target Info |
Antagonist |
[1]
|
|---|
|
KEGG Pathway
|
Calcium signaling pathway
|
|
cGMP-PKG signaling pathway
|
|
cAMP signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
Endocytosis
|
|
Adrenergic signaling in cardiomyocytes
|
|
Gap junction
|
|
Salivary secretion
|
|
Dilated cardiomyopathy
|
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Beta1 adrenergic receptor signaling pathway
|
|
PathWhiz Pathway
|
Muscle/Heart Contraction
|
|
Reactome
|
Adrenoceptors
|
|
G alpha (s) signalling events
|
|
WikiPathways
|
Monoamine GPCRs
|
|
Calcium Regulation in the Cardiac Cell
|
|
GPCRs, Class A Rhodopsin-like
|
|
Endothelin Pathways
|
|
GPCR ligand binding
|
|
GPCR downstream signaling
|
| References |
| REF 1 | Administration of the cyclic peptide COR-1 in humans (phase I study): ex vivo measurements of anti-beta1-adrenergic receptor antibody neutralization and of immune parameters. Eur J Heart Fail. 2012 Nov;14(11):1230-9. |
|---|
